Ingmar Hoerr
21Patents
16h-index
10Co-inventors
74Inventor score
Filing activity: Dec 5, 2003 → Jun 28, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8217016B2 | Application of mRNA for use as a therapeutic agent for tumorous diseases | Human Necessities | 177 | Expired |
| US10188748B2 | Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions | Emerging Cross-Sectional Technologies | 65 | Active |
| US9155788B2 | Application of mRNA for use as a therapeutic against tumour diseases | Human Necessities | 56 | Active |
| US9226959B2 | Nucleic acids comprising formula (NuGlXmGnNv)a and derivatives thereof as immunostimulating agent/adjuvant | Emerging Cross-Sectional Technologies | 45 | Active |
| US11078247B2 | RNA encoding a therapeutic protein | Chemistry; Metallurgy | 38 | Active |
| US9655955B2 | Application of mRNA for use as a therapeutic against tumour diseases | Human Necessities | 34 | Active |
| US11135312B2 | Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions | Physics | 28 | Active |
| US10568972B2 | Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions | Emerging Cross-Sectional Technologies | 28 | Active |
| US9352028B2 | Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC) | Human Necessities | 24 | Active |
| US9402887B2 | Composition for treating prostate cancer (PCa) | Human Necessities | 23 | Active |
| US10434154B2 | Composition for treating prostate cancer (PCa) | Human Necessities | 23 | Active |
| US9433669B2 | Application of mRNA for use as a therapeutic against tumor diseases | Human Necessities | 22 | Active |
| US9439956B2 | Application of mRNA for use as a therapeutic against tumour diseases | Human Necessities | 22 | Active |
| US9463228B2 | Application of mRNA for use as a therapeutic against tumour diseases | Human Necessities | 22 | Active |
| US9433670B2 | Application of mRNA for use as a therapeutic against tumour diseases | Human Necessities | 22 | Active |
| US10441653B2 | Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant | Chemistry; Metallurgy | 22 | Active |
| US11421038B2 | RNA-coded antibody | Emerging Cross-Sectional Technologies | 11 | Active |
| US11369691B2 | Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions | Emerging Cross-Sectional Technologies | 10 | Active |
| US11596699B2 | RNA encoding an antibody | Emerging Cross-Sectional Technologies | 8 | Active |
| US12227549B2 | RNA encoding a therapeutic protein | Chemistry; Metallurgy | 0 | Active |
| US12048738B2 | Composition for treating prostate cancer (PCa) | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.